Table 3.

Follow-up assessments in the Japan REnal Denervation (J-RED) registry

	Before RDN	At RDN	Just after RDN	Mandatory 2-year follow-up after RDN				Optional 10-year follow-up after RDN
				3 mo	6 mo	12 mo	24 mo	3 yr	4 yr	5 yr	6 yr	7 yr	8 yr	9 yr	10 yr
Patient characteristics (disease history, height, etc.)	x
Body weight	x		x	x	x	x	x	x	x	x	x	x	x	x	x
RDN procedure		x
Office BP (trough)	x		x	x	x	x	x	x	x	x	x	x	x	x	x
24 h ABPM	x			x	x	x	x	x	x	x	x	x	x	x	x
Home BP measurement (5 days)	x			x	x	x	x	x	x	x	x	x	x	x	x
Blood tests	x		x	x	x	x	x	x	x	x	x	x	x	x	x
Creatinine	x		x	x	x	x	x	x	x	x	x	x	x	x	x
NT-proBNP	x		x	x	x	x	x	x	x	x	x	x	x	x	x
HbA1c	x		x	x	x	x	x	x	x	x	x	x	x	x	x
LDL cholesterol	x		x	x	x	x	x	x	x	x	x	x	x	x	x
Proteinuria	x		x	x	x	x	x	x	x	x	x	x	x	x	x
ECG, LVH, SV1 + RV5 mm	x		x	x	x	x	x	x	x	x	x	x	x	x	x
Atrial fibrillation	x		x	x	x	x	x	x	x	x	x	x	x	x	x
Renal artery assessment
Angiography		x
Computed tomography	x				x
Clinical outcomes (ASCVD, HF, diabetes, CKD, AF, hypotension, CV death, all-cause death) & complications				x	x	x	x	x	x	x	x	x	x	x	x
Antihypertensives (number of classes & dose)	x			x	x	x	x	x	x	x	x	x	x	x	x

ABPM ambulatory blood pressure monitoring, AF atrial fibrillation, ASCVD atherosclerotic cardiovascular disease, BP blood pressure, CKD chronic kidney disease, CV cardiovascular, ECG electrocardiogram, HbA1c glycosylated haemoglobin, HF heart failure, LDL low-density lipoprotein, LVH left ventricular hypertrophy, mo months, NT-proBNP N-terminal pro B-type natriuretic peptide, RDN renal denervation, SV1 + RV5 electrocardiogram criteria used in the diagnosis of left ventricular hypertrophy, yr years